Stoke Therapeutics Inc (NASDAQ:STOK) shares, rose in value on Friday, July 11, with the stock price down by -1.50% to the previous day’s close as strong demand from buyers drove the stock to $11.86.
Actively observing the price movement in the last trading, the stock closed the session at $12.04, falling within a range of $11.7603 and $12.03. The value of beta (5-year monthly) was 1.102 whereas the PE ratio was 15.08 over 12-month period. Referring to stock’s 52-week performance, its high was $16.15, and the low was $5.35. On the whole, STOK has fluctuated by 4.40% over the past month.
With the market capitalization of Stoke Therapeutics Inc currently standing at about $647.52 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that STOK’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 100% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of STOK currently trading nearly 1.42% and 11.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.34, while the 7-day volatility ratio is showing 4.19% which for the 30-day chart, stands at 4.49%. Furthermore, Stoke Therapeutics Inc (STOK)’s beta value is 1.14.
A comparison of Stoke Therapeutics Inc (STOK) with its peers suggests the former has fared considerably weaker in the market. STOK showed an intraday change of -1.50% in last session, and over the past year, it grew by 7.52%%.
Data on historical trading for Stoke Therapeutics Inc (NASDAQ:STOK) indicates that the trading volumes over the past 10 days have averaged 0.58 and over the past 3 months, they’ve averaged 664.02K. According to company’s latest data on outstanding shares, there are 54.60 million shares outstanding.
Nearly 16.02% of Stoke Therapeutics Inc’s shares belong to company insiders and institutional investors own 98.77% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.11 million shares as on 2025-06-13, resulting in a short ratio of 20.21. According to the data, the short interest in Stoke Therapeutics Inc (STOK) stood at 2683.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 11.67 million. The stock has fallen by -11.36% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the STOK stock heading into the next quarter.
